Based in New Jersey, Becton, Dickinson and CompanyBDX is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its fourth-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today's Zacks #1(Strong Buy) Rank stocks here. ) We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson's adjusted earnings of $2.40 per share beat the Zacks Consensus Estimate by 2 cents and increased from $2.12 posted in the year-ago quarter.
Revenues: Reported revenues amounted to $3.166 billion down from $3.231 billion in the year-ago period. Revenues however came above the Zacks Consensus Estimate of $3.136 billion.
Key Stats: The company expects fiscal 2018 revenues to increase 5% to 6%. The company expects adjusted diluted earnings per share to be between $10.55 and $10.65 on a stand-alone basis, which represents growth of approximately 12%.
Becton, Dickinson and Company Price and EPS Surprise
Major Factors: BD Medical generated revenues of $2.115 billion, down 5.3% on a year-over-year basis.
BD Life sciences generated revenues of $1.051 billion, up 5.5% from the year-ago quarter.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report